BPC-157 and night sweats: what we know
Night sweats appear in BPC-157 user reports but not in any published study. Here is what the evidence and the likely mechanism actually show.
Why we wrote this. A recurring community signal with no published explanation. We traced the plausible mechanism and named what the data can and cannot support.
In this article (5 sections)
Night sweats appear repeatedly in community reports from people using BPC-157: readers describe waking soaked in sweat while on the peptide, with the symptom disappearing when they stop and returning when they restart[1]. The pattern is consistent enough to be worth taking seriously. It is not, however, documented in any published study, because no clinical trial of BPC-157 has run long enough, in enough participants, to generate an adverse-event table that would catch it.
What the published human safety data covers
The published human safety record for BPC-157 is very thin. A 2025 pilot study (Lee and Burgess) administered intravenous BPC-157 to two healthy adults at doses of 10 mg on day one and 20 mg on day two[2]. The researchers found no measurable effects on heart, liver, kidney, thyroid, or blood-glucose markers, and no side effects were reported. Night sweats were not mentioned. The study ran for two consecutive days with two participants, so it had no power to catch effects that emerge over weeks of use.
Preclinical toxicology in mice, rats, rabbits, and dogs (Xu et al. 2020) found that BPC-157 "was well tolerated and did not cause any serious toxicity" across single-dose, repeated-dose, genotoxicity, and embryo-fetal toxicity protocols[3]. The only notable finding was a transient creatinine decrease in dogs at 2 mg/kg, which resolved after two weeks. Sweating was not assessed, because rodents and dogs regulate body temperature primarily through panting rather than sweat glands.
The most plausible mechanism: nitric oxide and vasodilation
One of the better-characterised effects of BPC-157 in animal models is vasodilation via the nitric oxide (NO) pathway. A 2020 study published in Scientific Reports found that BPC-157 causes "concentration-dependent vasodilation" in isolated rat aortas by activating a Src-Caveolin-1-eNOS signalling cascade[4]. The sequence is: BPC-157 activates the Src protein, which phosphorylates Caveolin-1, releasing it from eNOS (endothelial nitric oxide synthase). Free eNOS then generates nitric oxide, which relaxes smooth muscle in vessel walls.
Vasodilation shifts blood flow toward the periphery. When that shift is pronounced enough, or happens during sleep when the body is already working to regulate core temperature, the hypothalamus can interpret peripheral heat as a need to cool down. One way the body cools down is by sweating. This is the same mechanism thought to drive the hot flushes and night sweats associated with certain blood-pressure medications and hormonal changes: peripheral vasodilation triggers a thermoregulatory response.
This is a plausible explanation, not a confirmed one. No study has directly connected BPC-157's eNOS activity to night sweats in humans. It is a mechanistic inference, not a measured outcome.
Other possible contributors
BPC-157 modulates the dopamine and serotonin systems in animal models. Serotonin plays a role in thermoregulation, and disruption of serotonin signalling is one of the proposed mechanisms behind medication-related night sweats. Whether BPC-157's serotonin-related activity is strong enough to affect thermoregulation in humans is not known.
Product purity is also a variable that community reports cannot control for. BPC-157 is sold by grey-market vendors with no regulatory oversight and no standardised manufacturing. Contaminants, incorrect concentrations, or other peptide fragments in the product could explain some reported effects, including temperature dysregulation, without implicating BPC-157 itself.
What community reports can and cannot tell us
The r/peptides discussion that prompted this article[1] describes users who have run deliberate on-off cycles and consistently reproduced the sweating. That kind of repeated personal observation is meaningful as a hypothesis generator. It is not meaningful as safety data, because it lacks controls, blinding, dose standardisation, product-identity verification, and the kind of systematic collection that would let you estimate how common the effect is or how it relates to dose or route of administration.
The short version: the community signal is real enough to write about and to ask a clinician about. It is not strong enough to establish that BPC-157 causes night sweats in any pharmacologically specific sense.
What to do if you are experiencing this
Night sweats that are severe, persistent, or accompanied by other symptoms (fever, unexpected weight loss, drenching that soaks sheets rather than causes dampness) have a long differential that includes conditions requiring medical evaluation. The pattern of sweating that appears with BPC-157 use and resolves on cessation is an anecdotal signal, not a diagnosis. If you are experiencing night sweats while using any unregulated peptide, the right first step is to stop and consult a clinician. For the regulatory and legal picture of BPC-157 by country, see BPC-157 legal status and regulation.
Frequently asked
Does BPC-157 cause night sweats?
No published study has documented night sweats as a side effect of BPC-157. Community reports describe the pattern, but they lack controls and dose verification. The most plausible mechanism is peripheral vasodilation via the nitric-oxide pathway, which can trigger thermoregulatory sweating, but this has not been directly tested in humans.
Why would BPC-157 cause sweating if it has no listed side effects?
BPC-157 has no approved label and therefore no official adverse-event list. The absence of a listed side effect reflects the absence of clinical trial data, not a confirmed clean record. The preclinical toxicology and the two published human safety studies did not assess sweating, and they ran for too short a duration to capture effects that emerge over weeks of use.
Does the route of administration (injectable vs oral) affect the likelihood of night sweats?
This has not been studied. Community reports mention both injectable and oral BPC-157 in connection with night sweats. If the mechanism is vasodilation, injectable routes may produce stronger systemic effects due to higher bioavailability, but this is speculation. No comparative data exists.
Should I stop using BPC-157 if I develop night sweats?
Any unexpected symptom while using an unregulated compound is a reason to pause and speak to a clinician. Night sweats that are drenching, persistent, or accompanied by other symptoms such as fever or unexplained weight loss warrant medical evaluation regardless of what you are taking, because the differential is broad.
Sources
- [1]r/Peptides: Has anyone else experienced night sweats from BPC-157? (community thread, 2025)Tier 3 · community↩
- [2]Lee E, Burgess K (2025): Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (Alternative Therapies in Health and Medicine; PMID 40131143)Tier 2 · expert↩
- [3]Xu et al. (2020): Preclinical safety evaluation of body protective compound-157 (Regulatory Toxicology and Pharmacology; PMID 32334036)Tier 1 · primary↩
- [4]Hsieh et al. (2020): Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway (Scientific Reports; PMID 33051481)Tier 1 · primary↩
No revisions yet. First published .